Author： Burnier M. Brunner H.
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.6, Iss.5, 1997-05, pp. : 489-500
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Angiotensin II receptor antagonists challenge ACE inhibitors
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. :
Access to resources
Recommend
Comparative Safety and Tolerability of Angiotensin II Receptor Antagonists
Drug Safety, Vol. 21, Iss. 1, 1999-07 ,pp. :
Angiotensin II receptor antagonists not yet the ELITE
Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. :
Angiotensin II receptor antagonists have similar efficacy
Inpharma, Vol. 1, Iss. 1243, 2000-01 ,pp. :
Risk-benefit assessment of angiotensin II receptor antagonists
Expert Opinion on Drug Safety, Vol. 1, Iss. 2, 2002-07 ,pp. :